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Background: Although statin therapy is beneﬁcial for the prevention of initial stroke, the beneﬁt for recurrent stroke
and its subtypes remains to be determined in Asian, inwhomstroke proﬁles are different fromCaucasian. This study
examined whether treatment with low-dose pravastatin prevents stroke recurrence in ischemic stroke patients.
Methods: This is a multicenter, randomized, open-label, blinded-endpoint, parallel-group study of patients who
experienced non-cardioembolic ischemic stroke. All patients had a total cholesterol level between 4.65 and
6.21 mmol/L at enrollment, without the use of statins. The pravastatin group patients received 10 mg of prava-
statin/day; the control group patients receivedno statins. The primary endpointwas the occurrence of stroke and
transient ischemic attack (TIA), with the onset of each stroke subtype set to be one of the secondary endpoints.
Finding: Although 3000 patients were targeted, 1578 patients (491 female, age 66.2 years) were recruited and
randomly assigned to pravastatin group or control group. During the follow-up of 4.9 ± 1.4 years, although
total stroke and TIA similarly occurred in both groups (2.56 vs. 2.65%/year), onset of atherothrombotic infarction
was less frequent in pravastatin group (0.21 vs. 0.64%/year, p= 0.0047, adjusted hazard ratio 0.33 [95%CI 0.15 to
0.74]). No signiﬁcant intergroup difference was found for the onset of other stroke subtypes, and for the occur-
rence of adverse events.
Interpretation: Althoughwhether low-dose pravastatin prevents recurrence of total stroke or TIA still needs to be
examined in Asian, this study has generated a hypothesis that it may reduce occurrence of stroke due to larger
artery atherosclerosis.
Funding: This study was initially supported by a grant from the Ministry of Health, Labour and Welfare, Japan.
After the governmental support expired, it was conducted in collaboration between Hiroshima University and
the Foundation for Biomedical Research and Innovation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).oscience and Therapeutics, HiroshimaUniversity Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi,Minami-ku,
oto).
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
dicine 2 (2015) 1071–10781. Introduction3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors, referred as statins, are widely used to improve serum lipid
proﬁles. In addition to the established value for coronary protection,
statins are thought to be beneﬁcial for stroke prevention. Indeed, statin
use was associated with 19 to 46% reduction of stroke risk (Pearson,
1998; Plehn et al., 1999; White et al., 2000; Sever et al., 2003; Kushiro
et al., 2009; Nomura et al., 2015). However, these ﬁndings were derived
from patients without prior stroke, and such preventive effect is less
robust for patients with occurred stroke. For instance, in the Stroke
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
trial, the use of atorvastatin was associated with 16% reduction in the
risk for recurrent stroke (Amarenco et al., 2006). Also, a meta-analysis
of 8 studies demonstrated that statin therapy has only a marginal effect
to reduce occurrence of subsequent stroke in patients with prior stroke
or transient ischemic stroke (TIA) (Manktelow and Potter, 2009).
Indeed, stroke is a heterogeneous disease with different etiologies,
with or without underlying arterial pathologies. Thus, the beneﬁts of
statins may be different depending on the subtypes of stroke. For
instance, given the structural difference betweenmajor cerebral arteries
and the perforating branches, the effects of statins can differ between
atherothrombotic and lacunar infarctions. Moreover, the use of statins
might increase the risk of hemorrhagic stroke (Amarenco et al., 2006;
Collins et al., 2004; Boekholdt et al., 2014). Nevertheless, the majority
of prior studies deﬁned stroke as a whole, with no distinction between
subtypes. Also, although the current international guidelines uniformly
recommend the use of statins for secondary stroke prevention
(European Stroke Organisation Executive Committee and ESO Writing
Committee, 2008; Usherwood, 2013; Kernan et al., 2014), prevalence
of lacunar infarction and cerebral hemorrhage is substantially higher
in Asian than in Caucasian, requiring further studies to determine
whether such guidelines are readily applicable to Asian.
Thus, this study examined whether pravastatin, a traditional statin
widely prescribed in the clinic, reduces recurrence of stroke and the
respective subtypes in non-cardioembolic stroke patients. Also, whether
the use of pravastatin favorably impacts on the occurrence of other
vascular events and stroke-related functional outcome was explored.
2. Methods
2.1. Patients
The design and baseline data of this prospective randomized, open-
labeled, blinded-endpoint (PROBE) study was reported previously
(Nagai et al., 2014). Brieﬂy, patients aged 45 to 80 years with a history
of non-cardioembolic ischemic stroke within the preceding one month
to three years were enrolled from 123 centers, between March 2004
and February 2009. All patients had a total cholesterol level between
4.65 and 6.21 mmol/L (180 to 240 mg/dL) at enrollment, without use
of statins. The major exclusion criteria included cerebral infarction of
determined rare etiology, infarction associated with catheterization or
surgery, and preferred use of statins for the treatment of co-morbid
coronary artery disease.
This study (NCT00221104) was conducted under the health insur-
ance system of Japan, in accordance with the Declaration of Helsinki
and the Ethical Guidelines on Clinical Studies of the Ministry of Health,
Labour andWelfare of Japan. Also, this study was approved by the insti-
tutional reviewboard of each participating center, andwritten informed
consent was obtained from all patients.
2.2. Procedures
Patients were enrolled via a web-based registration and follow-up
system provided by the data center, which automatically judged
eligibility of each patient and randomly assigned them to pravastatin
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statin use and hemorrhagic stroke (Nakamura et al., 2006), and under
higher prevalence of cerebral hemorrhage in Japanese (Ikeda et al.,
2014), dose of 10 mg/day was chosen, which is the approved standard
dose in the nation. In the pravastatin group, the administration was
initiated within 1 month after randomization, and the treatment was
continued until ﬁnal observation. Diet and exercise therapies were rein-
forced when the total cholesterol levels consistently exceeded 6.21
mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin
dose or addition of other non-statin drugs (such as ion exchange resin,
eicosapentaenoic acid, and ezetimibe) was allowed only when such
reinforcements were insufﬁcient. Even under such conditions, use of
other statins (such as simvastatin and atorvastatin) was prohibited. In
the control group, administration of any statinwas prohibited, although
use of other non-statin drugs was allowed when necessary.
After randomization, patients were followed up at 2 and 6 months,
and annually until the study completion. When patient underwent
recurrent stroke or other vascular events, such event information was
sent to the data center, and managed by dedicated data managers. Brain
MRI or CT imaging was performed as previously described (Nagai et al.,
2014), so was the measurement of total cholesterol, low density lipopro-
tein (LDL) cholesterol, triglyceride, and high density lipoprotein (HDL)
cholesterol. Treatment compliance was monitored at every clinical visit.
The primary endpoint was the onset of stroke and TIA. Secondary
endpoints were the onset of each stroke subtype, myocardial infarction,
vascular accident, death, hospitalization, dependence in activities of
daily living (modiﬁed Rankin Scale, mRS), degree of disability (Barthel
Index, BI), onset of dementia, and severity of cognitive impairment.
Particularly, stroke and other vascular events were adjudicated by the
central event evaluation committees, organized by 4 neurologists for
stroke events and 3 cardiologists for cardiac events. The committees
were annually held during the study period, in which each event was
carefully reviewed based on reports submitted from the participating
centers, in a manner strictly blinded from the allocated group informa-
tion. Also, each event was evaluated in accordance with the predeﬁned
deﬁnition, the details of which were previously reported (Nagai et al.,
2014). For the adjudication of events, the ﬁnal decision was made by
consensus of all committee members. Additionally, correctness of all
event adjudication was veriﬁed by a local neurologist or cardiologist
in each participating center, by collating it with the patient medical
records. Dementia was diagnosed by the diagnostic and statistical
manual of mental disorders-IIIR criteria. Severity of cognitive impair-
ment was assessed by the clinical dementia rating (CDR) score and
the mini-mental state examination (MMSE) score.
2.3. Statistical Analysis
In accordancewith the intention-to-treat (ITT) principle, the efﬁcacy
analysis set was deﬁned as ITT population, including all randomized
patients. The safety analysis set included patients who received at
least one dose of study drug in the pravastatin group and all patients
who were assigned to the control group. Also, the per protocol set was
deﬁned by excluding patients with no evaluation of primary endpoint
and by additionally excluding patients who took less than 1/4 of prava-
statin (as averaged from respective clinical visits) in the pravastatin
group and those who took any kind of statins in the control group.
The cumulative incidences of time to the ﬁrst event were estimated by
the Kaplan–Meier method. The cumulative incidence curves for the
two groups were compared by log-rank test adjusted for the stratiﬁca-
tion factors at randomization: i.e., stroke subtype (atherothrombotic
infarction vs. others), high blood pressure (≥150/90 mm Hg vs. not),
and diabetes mellitus (absence vs. presence). The Cox proportional
hazard model was used to estimate the hazard ratio (HR) and the 95%
conﬁdence interval (CI) by adjusting such stratiﬁcation factors.
Changes of mRS, BI, CDR, and MMSE from the baseline were compared
by mixed-effects model with repeated measurements (MMRM) with
1073N. Hosomi et al. / EBioMedicine 2 (2015) 1071–1078visits deﬁned as ﬁxed effect and baseline values as covariates. In pa-
tients without dementia at enrollment, occurrence of dementia was
compared between the groups by χ2 test. The levels of total cholesterol,
LDL cholesterol, triglyceride and HDL cholesterol, and blood pressures
were also compared by MMRM.
All analyses were predeﬁned in the statistical analysis plan before
the database lock in September 2014, and were conducted using SAS
version 9.3 (Cary, NC, USA). Data were expressed as the mean ±
standard deviation (SD) for continuous variables and as frequencies
and percentages for discrete variables, unless speciﬁcally mentioned.
The level of signiﬁcance was set at p b 0.05 (2-tailed).
2.4. Role of the Funding Source
This study was initially supported by grants (H14-023, H15-020,
H16-003, H17-004) from the Ministry of Health, Labour and Welfare,
Japan. After the governmental support expired, it was conducted in col-
laboration between Hiroshima University Graduate School of Biomedi-
cal and Health Sciences and the Foundation for Biomedical Research
and Innovation. The latter organization receives unconditional research
grants from several pharmaceutical companies, including DAIICHIFig. 1. TrialSANKYO CO., LTD., which commercializes pravastatin. However, the
company was not involved in the design and execution of this study.
Also, the company did not provide pravastatin for this study and has
not reviewed the current manuscript.3. Results
The 1589 patients were randomly allocated to the pravastatin or
control group (Fig. 1). However, due to ineligibility found after random-
ization or overlapped registration, 4 patients in the pravastatin group
and 7 patients in the control group were excluded, resulting in 1578
patients (793 in pravastatin group, 785 in control group) for
intention-to-treat analysis. Also, in the pravastatin group, 13 patients
(1.6%) did not take pravastatin and 11 patients (1.4%) had no evaluation
of primary endpoint. In the control group, 7 patients (0.9%) had no eval-
uation of primary endpoint. Also, 143 patients (18.0%) in pravastatin
group took less than 1/4 of prescribed drug, and 104 patients (13.2%)
in control group received certain kinds of statins during the follow-up
(Supplementary Table S1). Final follow-up rateswere 79.3% in the prav-
astatin group and 80.4% in the control group.proﬁle.
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strating no signiﬁcant difference in parameters between the two
groups. Particularly, lipid and blood pressure levels, proportions of
stroke subtypes, and use of antiplatelet agents were well balanced
between the two groups. During the follow up, total cholesterol, LDL
cholesterol, and triglyceride levels were lower in pravastatin group
(Fig. 2A–C), whereas HDL cholesterol level was slightly higher in
pravastatin group (Fig. 2D). Also, change of systolic and diastolic blood
pressure was similar between the two groups (Fig. 2E,F), so was the
duration of follow-up (4.86 ± 1.45 vs. 4.93 ± 1.44 years, respectively).
As the primary endpoint, total stroke and TIA similarly occurred in
pravastatin and control group (2.56 vs. 2.65%/year, p = 0.82, adjusted
HR 0.97 [95%CI 0.73 to 1.29], Fig. 3A), and the ﬁnding was virtually un-
affected when TIA was excluded from the analysis (2.35 vs. 2.47%/year,
p = 0.74, adjusted hazard ratio 0.95 [95%CI 0.71 to 1.28]). However,
occurrence of atherothrombotic infarction was less frequent in the
pravastatin group (0.21 vs. 0.65%/year, p = 0.0047, adjusted HR 0.33
[95%CI 0.15 to 0.74], Fig. 3B). Additionally, such trend was present in
patients both with atherothrombotic and lacunar infarction at baseline
(Supplementary Table S2), and appeared to exist in certain subgroups
of patients (Supplementary Fig. S2). Occurrence of lacunar infarction
(Fig. 3C), cardioembolic infarction (Fig. 3D), and intracranial hemor-
rhage (Fig. 3E) was similar between the two groups, so was the occur-
rence of myocardial infarction, vascular accidents, death, and
hospitalization (Table 2).
As stroke-related functional measures, changes of mRS scores and BI
score were similar between the two groups (Fig. 4A,B), so was the
change of CDR score (Fig. 4C). Decline of MMSE score tended to be
mild in the pravastatin group, although the difference was not signiﬁ-
cant (Fig. 4D). Also, in patients without dementia at enrollment,
incidence of newly diagnosed dementia was 4.1% (0.85%/year) in
pravastatin group and 4.2% (0.84%/year) in control group (p = 0.94).
Signiﬁcant intergroup differences were not found in the occurrence
of adverse events, including cancer, rhabdomyolysis, and laboratory
examinations (Supplementary Table S3).Table 1
Baseline characteristics.
Pravastatin group
n = 793
Control group
n = 785
Age, years 66.1 ± 8.4 66.4 ± 8.6
Male, n (%) 545 (68.7) 542 (69.0)
Height, cm 160.4 ± 8.8 160.1 ± 8.6
Weight, kg 61.5 ± 10.2 60.7 ± 10.1
Body mass index, kg/m2 23.8 ± 3.1 23.6 ± 3.0
Total cholesterol, mmol/L 5.45 ± 0.62 5.42 ± 0.64
HDL cholesterol, mmol/L 1.39 ± 0.41 1.37 ± 0.41
LDL cholesterol, mmol/L 3.35 ± 0.63 3.35 ± 0.64
Triglyceride, mmol/L 1.61 ± 0.85 1.60 ± 0.82
Hypertension, n (%) 596 (75.2) 604 (76.9)
Systolic blood pressure, mm Hg 137.3 ± 17.6 136.9 ± 18.0
Diastolic blood pressure, mm Hg 79.3 ± 11.6 79.4 ± 10.9
Diabetes mellitus, n (%) 185 (23.3) 184 (23.4)
Fasting blood glucose, mmol/L 6.56 ± 2.38 6.49 ± 2.17
Coronary artery disease, n (%) 37 (4.7) 44 (5.6)
Chronic kidney disease, n (%) 195 (24.6) 183 (23.3)
Creatinine, md/dL 0.81 ± 0.21 0.80 ± 0.21
Smoking habit
Smoker, n (%) 426 (53.7) 420 (53.5)
Non-smoker, n (%) 358 (45.1) 352 (44.8)
Unknown, n (%) 9 (1.1) 13 (1.7)
Use of antiplatelet agents, n (%) 723 (91.2) 715 (91.1)
Ischemic stroke subtype
Atherothrombotic infarction, n (%) 195 (24.6) 206 (26.2)
Lacunar infarction, n (%) 502 (63.3) 504 (64.2)
Infarction of undetermined etiology, n (%) 96 (12.1) 75 (9.6)
No parameters were signiﬁcantly different between the pravastatin and control groups.4. Discussion
As previously reported (Nagai et al., 2014), although the sample size
was initially set to be 3000, the target number was not achieved and
1589 patients were recruited for this study (Fig. 1), largely due to the
narrower window of patient recruitment. Also, several patients were
excluded after randomization, resulting in 1578 patients for the
intention-to-treat analysis. Randomization was successfully conducted
and both group of patients demonstrated similarly well controlled
cardiovascular risk factor proﬁles at enrollment (Table 1), representing
a population at lower risk for stroke recurrence. Also, use of anti-platelet
agents exceeded 90% in both groups, which could have even reduced
the risk for stroke recurrence. Of note, proportions of stroke subtypes
were similar between the two groups, with roughly two thirds of
patients having lacunar infarction, which was two times higher than
reported in SPARCL trial (Amarenco et al., 2009), but similar to the
recent report from Japan (Shinohara et al., 2010).
Although the dose of pravastatin (10 mg/day) was lower than used
in studies from the Western countries (Shepherd et al., 2002; ALLHAT
Ofﬁcers and Coordinators for the ALLHAT Collaborative Research
Group, 2002), it was the approved standard dose in Japan. Indeed, the
levels of total cholesterol and LDL cholesterol were substantially
reduced and kept in the normal ranges in the pravastatin group
(Fig. 2A,B). Also, level of HDL cholesterol was slightly higher in the
pravastatin group (Fig. 2D), which could have exerted favorable impact
on arteries in this group of patients (Kuwashiro et al., 2012; Nishimura
et al., 2013). As a well-deﬁned stroke risk factor, blood pressure level
was similarly well controlled in both groups (Fig. 2E,F), making it
unlikely that the level exerted signiﬁcant inﬂuence on the recurrence
of stroke in either group.
Given the nature of study sample, incidence of recurrent stroke
(approximately 2.6%/year in both groups)was roughly half of our initial
assumption, but turned out to be similar to the recent report from Japan
(Shinohara et al., 2010). As the primary endpoint, although total stroke
recurrence was similar between the two groups, patient accrual was
insufﬁcient and statistical power was not enough, requiring further
studies to adequately address to the intergroup difference. However,
even under such conditions, onset of atherothrombotic infarction was
clearly less frequent in pravastatin group, whereas no signiﬁcant differ-
ence was found for other stroke subtypes (Fig. 3). This ﬁnding may be
reasonable, if pravastatin exerted atheroprotective effects on the carotid
and major cerebral arteries (Crisby et al., 2001; Byington et al., 1995;
Crouse et al., 2007), thus suppressing the progression of underlying ath-
erosclerotic processes. However, how levels of LDL cholesterol or other
pleiotropic effects have contributed to the risk reduction cannot be de-
termined from this study. Of note, reduction of LDL cholesterol was
roughly 20% in this study, compared to the baseline (Fig. 2B), which
may not be an effective reduction for stroke prevention (Boekholdt
et al., 2014; Corvol et al., 2003; Amarenco et al., 2004). On the other
hand, many studies have suggested pleiotropic effects of statins, includ-
ing atheromatous plaque stabilization and anti-inﬂammation (Crisby
et al., 2001; Byington et al., 1995; Crouse et al., 2007; Tsuda et al.,
1996; Ridker et al., 1999; Albert et al., 2001; Uchiyama et al., 2009),
which could have played a role for the suppression of atherothrombotic
infarction as found in this study. Concurrentwith this study, sub-studies
focusing on chronic inﬂammation (NCT00361699) and carotid athero-
sclerosis (NCT00361530) were conducted, the results of which would
allow for additional elucidation on the relationship between stroke
recurrence and statin use.
Additionally, incidence of lacunar infarctionwas similar between the
two groups, or tended to be even higher (not signiﬁcant) in the prava-
statin group (Fig. 3C). On the basis of this ﬁnding, pravastatin is not
likely to suppress the stroke of small arterial pathologies, as generally
referred to “small vessel disease.” However, stroke patients often have
underlying cardiovascular complications and risk factors, for which util-
ity of statin treatments should not be undervalued. Of note, although
Fig. 2.Changes in lipid proﬁle and bloodpressure. Changes in the lipid proﬁle and blood pressurewere analyzedbymixed-effectsmodelwith repeatedmeasurements (MMRM). Open and
close circles represent adjustedmean, with standard error expressed by error bars. Levels of total cholesterol (A), low density lipoprotein (LDL) cholesterol (B), and triglyceride (C) were
lower in the pravastatin group. Level of high density lipoprotein (HDL) cholesterol was higher in the pravastatin group (D). Systolic blood pressure (E) and diastolic blood pressure
(F) were appropriately controlled in the normal ranges in both groups. Mean values (mean ± SE) of total cholesterol during follow-up periods in pravastatin group and control group
were 4.75 ± 0.02 vs. 5.32 ± 0.02 mmol/L, LDL cholesterol 2.67 ± 0.02 vs. 3.22 ± 0.02 mmol/L, triglyceride 1.45 ± 0.02 vs. 1.52 ± 0.02 mmol/L, HDL cholesterol 1.44 ± 0.01 vs.
1.40 ± 0.01 mmol/L, systolic blood pressure 134.1 ± 0.38 vs. 134.4 ± 0.38 mm Hg, and diastolic blood pressure 76.8 ± 0.25 vs. 77.4 ± 0.25 mm Hg, respectively.
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(Amarenco et al., 2006; Boekholdt et al., 2014), the occurrence was
virtually the same between two groups (Fig. 3E). In a meta-analysis by
Boekholdt et al., the risk for intracranial hemorrhage was higher in
patients with very low LDL cholesterol level (b1.94mmol/L) than in pa-
tients with moderately low LDL cholesterol level (2.58 to 3.23 mmol/L)
(Boekholdt et al., 2014). In the current study, LDL cholesterol level in the
pravastatin group was only “moderately low” (2.67 mmol/L, Fig. 2B),
and was substantially higher than in SPARCL trial (1.89 mmol/L) in
which risk of hemorrhagic strokewas increased (Amarenco et al., 2006).
As stroke-related functional measures, mRS and BI similarly deterio-
rated in both groups (Fig. 4A,B), with no apparent difference. Also, given
the studies suggesting favorable effects of statin on cognitive function,
whether change of CDR and MMSE score differs between the two
groups was of interest. In the current study, CDR score similarly deteri-
oratedduring the time course in both groups (Fig. 4C). However, decline
of MMSE score tended to be less in the pravastatin group although the
change was not signiﬁcant (Fig. 4D), which may be in line with aprevious meta-analysis, suggesting an effect of statins for mitigating
decline of MMSE score (McGuinness et al., 2014). Additionally,
incidence of newly diagnosed dementia was relatively low as in prior
studies (Forette et al., 1998; Tzourio et al., 2003), with no signiﬁcant
difference between the groups. Further studies are required to deﬁne
the impact of statin on cognitive function and dementia.
The current study has certain limitations. First, in part because of the
restriction of national health insurance system, this study was conduct-
ed by the PROBE method, potentially allowing for arbitrariness in the
endpoint evaluation. Under such condition, we made every effort to
increase accuracy of event adjudication. Particularly, all stroke and
other vascular events were reviewed by the dedicated central event
evaluation committees in a strictly blinded manner. Also, all events
were adjudicated precisely in accordancewith the predeﬁned deﬁnition
(Nagai et al., 2014), to prevent inconsistent judgment between commit-
tee members and between occasions. Second, although all stroke and
other vascular events were cautiously reviewed and adverse events
were eagerly collected, how lack of blinding impacted on reporting
Fig. 3. Kaplan–Meier curves for the primary and secondary endpoints. Although stroke and TIA similarly occurred in the pravastatin and control groups (A), occurrence of
atherothrombotic infarctionwas less frequent in the pravastatin group (B). Occurrence of lacunar infarction (C), cardioembolic infarction (D), and intracranial hemorrhage (E)was similar
between the two groups. Hazard ratios are adjusted for the stratiﬁcation factors at randomization: i.e., stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/
90 mm Hg vs. not), and diabetes mellitus (absence vs. presence).
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conducted as part of the clinical practice, we could not strictly prohibit
the use of statins in the control group. Indeed, in part because of the
study demonstrating favorable effects of statins for stroke prevention
(Amarenco et al., 2006), more than 10% of patients in the control
group took some kinds of statins. Inversely, nearly 20% of patients in
the pravastatin group did not take pravastatin or took less than 1/4 of
prescribed pravastatin. However, such protocol violations would dilute
intrinsic differences between the groups and decrease the likelihood ofTable 2
Incidence of vascular events other than stroke.
Event rate, %/year Adjusted
hazard ratio
95% conﬁdence
interval
p
value
Pravastatin Control
Myocardial
Infarction
0.10 0.18 0.55 0.16 to 1.89 0.34
Vascular Accidents 3.23 3.81 0.85 0.66 to 1.09 0.19
Death 1.11 0.90 1.23 0.79 to 1.93 0.36
Hospitalization 9.25 9.73 1.02 0.85 to 1.22 0.85
Hazard ratios are adjusted for the stratiﬁcation factors at randomization: i.e., stroke sub-
type (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mm Hg vs.
not), and diabetes mellitus (absence vs. presence).achieving statistical signiﬁcance. Under such conditions, the robustness
of our analyses was tested for the per protocol analysis set (Fig. 1). By
such sensitivity analysis, intergroup difference in the occurrence of
atherothrombotic infarction persisted (0.15 vs. 0.55%/year, p =
0.0047, adjustedHR 0.26 [95%CI 0.10 to 0.71]), supporting the reliability
of our ﬁnding.
5. Conclusion
Althoughwhether low-dose pravastatin prevents recurrence of total
stroke or TIA still needs to be examined in Asian, this study has generated
a hypothesis that it may reduce occurrence of stroke due to larger artery
atherosclerosis.
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